Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Novo Nordisk's Victoza Adds CV Benefit Claim, But Not For Primary Prevention

Aug 28 2017

• By Sue Sutter

Diabetes

Related Content

<i>Brilinta</i> Approval Shows AstraZeneca's Success With Aspirin Theory, But Can It Change The Market?

Jul 25 2011

Novo’s Victoza CV Benefit Claim Could Be Narrowed With FDA Panel Vote

Jun 21 2017

Victoza’s Non-Cardio Safety May Dominate At FDA Panel Review

Jun 17 2017

Novo Readies For Victoza CV Benefit Claim With US FDA Panel Nod

Jun 21 2017

Jardiance's Cardiovascular Benefit Claim Bodes Well For Other Products Too

Dec 05 2016

Related Companies

Novo Nordisk A/S

Boehringer Ingelheim GmbH

Eli Lilly and Company

AstraZeneca PLC

Additional Topics

United States Approvals Advisory Committees Regulation BioPharmaceutical Metabolic Disorders

More from Approvals

More from Product Reviews

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window